In a bid to bolster its portfolio of liver disease drugs, Genfit has entered into an agreement to acquire Versantis for up to CHF 105 M (US$108.91 M). The deal provides Genfit access to Versantis’ investigational pipeline including lead asset, VS-01, a Phase II ready programme based on scavenging liposome technology for the treatment of acute-on-chronic liver failure (ACLF). The acquisition marks another milestone in the execution of Genfit’s strategic plan to become a leader in ACLF, after selling its non-alcoholic steatohepatitis (NASH) drug, elafibranor, to Ipsen in 2021 following disappointing Phase III data.